A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due …
…, S Vaidyanathan, A Marwah… - Expert opinion on …, 2021 - Taylor & Francis
Objective: Efficacy and safety of Itolizumab, an immunomodulatory mAb, in treating
moderate-to-severe acute respiratory distress syndrome (ARDS) due to cytokine release in COVID-…
moderate-to-severe acute respiratory distress syndrome (ARDS) due to cytokine release in COVID-…
Media milling process optimization for manufacture of drug nanoparticles using design of experiments (DOE)
V Nekkanti, A Marwah, R Pillai - Drug development and industrial …, 2015 - Taylor & Francis
Abstract Design of experiments (DOE), a component of Quality by Design (QbD), is
systematic and simultaneous evaluation of process variables to develop a product with …
systematic and simultaneous evaluation of process variables to develop a product with …
[HTML][HTML] Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic …
…, S Loganathan, S Deodhar, A Marwah… - Breast cancer research …, 2021 - Springer
Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is
well tolerated with similar efficacy (measured by overall response rate [ORR] and progression…
well tolerated with similar efficacy (measured by overall response rate [ORR] and progression…
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: results from …
…, G Singh, SMN Murugesan, A Marwah… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To establish equivalence in the pharmacokinetic (PK) and pharmacodynamic (PD)
endpoints between proposed biosimilar Insulin‐R (Biocon's Insulin‐R) and Humulin® R using …
endpoints between proposed biosimilar Insulin‐R (Biocon's Insulin‐R) and Humulin® R using …
Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic …
SR Joshi, G Singh, A Marwah, S Mittra… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To compare the clinical efficacy and safety of glargine‐U100 (Lantus/Gla‐100) with
glargine‐U300 (Toujeo/Gla‐300) in adult patients with type 2 diabetes (T2D) and type 1 …
glargine‐U300 (Toujeo/Gla‐300) in adult patients with type 2 diabetes (T2D) and type 1 …
Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: A randomized, active …
…, J Panda, A Marwah - Expert Opinion on …, 2022 - Taylor & Francis
Background Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil was compared
with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin glargine and …
with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin glargine and …
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small …
…, M Liu, TA Idris, SMN Murugesan, A Marwah… - European Journal of …, 2023 - Springer
Background and Objectives MYL-1402O is a bevacizumab (Avastin ® ) biosimilar.
Pharmacokinetic and safety similarity of MYL-1402O and reference Avastin ® authorized in the …
Pharmacokinetic and safety similarity of MYL-1402O and reference Avastin ® authorized in the …
[HTML][HTML] Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
…, HF Koch, S Loganathan, S Deodhar, A Marwah… - The Breast, 2021 - Elsevier
Background Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial
demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator …
demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator …
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results …
…, G Singh, SMN Murugesan, A Marwah… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of
proposed biosimilar insulin 70/30 (Biocon's Insulin‐70/30) and HUMULIN® 70/30 (HUMULIN‐70/…
proposed biosimilar insulin 70/30 (Biocon's Insulin‐70/30) and HUMULIN® 70/30 (HUMULIN‐70/…
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the …
…, N Sharma, J Panda, A Marwah… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of
proposed biosimilar Insulin N (Biocon's Insulin‐N; Biocon Biologics Ltd., Bangalore, India) and …
proposed biosimilar Insulin N (Biocon's Insulin‐N; Biocon Biologics Ltd., Bangalore, India) and …